细胞冷冻保存市场－2026-2031年预测

细胞冷冻保存市场预计将以 7.9% 的复合年增长率成长，到 2025 年达到 302,566,000 美元，到 2031 年达到 477,361,000 美元。

细胞冷冻市场（包括冷冻保存培养基、设备及相关耗材）是生命科学和生物技术产业中一个基础且快速成长的细分市场。冷冻保存是将细胞储存在超低温（通常低于-80°C或液态氮中）以终止所有生物活性并确保其长期存活和功能的过程。这项技术对于保存珍贵的生物材料至关重要，从研究细胞株和原代细胞到治疗性细胞产品均包含在内。细胞疗法的进步、生物生物银行基础设施的不断改进、保存通讯协定技术的持续改进以及慢性疾病的日益增多（推动了细胞研究的发展）共同驱动着市场扩张。

细胞疗法的加速研发和商业化是推动这一领域发展的关键且强大的动力。再生医学、免疫疗法和干细胞疗法等领域从根本上依赖可靠的冷冻保存技术。 CAR-T细胞疗法、间质干细胞疗法和其他先进治疗药物（ATMP）等疗法需要保存、运输和分发活细胞材料，同时确保其效力和功能不受影响。细胞冷冻保存技术是治疗研发和交付过程中不可或缺的组成部分，它能够实现现成的异体疗法，并确保自体疗法的可靠供应链。

同时，全球生物银行活动的扩张和规模化也带动了市场发展。用于学术研究、药物研发、临床试验和人群健康研究的生物样本库都依赖可靠的长期细胞储存。保存患者来源细胞、基因工程细胞株和疾病模型对于生物医学发现至关重要。机构、政府和私人对生物银行基础设施的投资直接转化为对高品质冷冻保存培养基、专用储存容器和可靠的低温储存系统的持续需求。

冷冻保护剂（CPA）和冷冻技术的进步是推动市场成长和应用拓展的关键因素。研究重点在于开发毒性较低、无血清，甚至在某些情况下不含二甲基亚砜（DMSO）的冷冻保存培养基，从而提高解冻后细胞的活力、恢復率和功能性。此外，一些创新技术也在研发中，例如可控冷却装置，这些装置能够优化冷却曲线，最大限度地减少冰晶形成和细胞损伤。对于临床和治疗应用而言，制定标准化的GMP级冷冻通讯协定尤其重要，因为在这些应用中，一致性和合规性至关重要。

全球慢性病和退化性疾病的日益增多，虽然是间接但却重要的市场驱动因素。癌症、心血管疾病、神经退化性疾病、糖尿病等疾病的研究越来越多地采用细胞模型、患者来源样本和基于细胞的筛检平台。这种活性化的研究活动产生了大量宝贵的细胞材料，这些材料需要保存以用于长期研究、实验重复和未来应用，从而推动了学术界和工业界实验室对可靠的冷冻保存解决方案的需求。

政府和机构对生命科学研究的支持也进一步推动了市场发展。用于干细胞研究、再生医学和个人化医疗的公共资助方案通常包含支援核心设施的条款，例如生物银行和冷冻保存能力，这促进了先进冷冻保存技术的应用，并为长期细胞储存的营运成本提供了支持。

北美凭藉其高度集中的生物技术和製药公司、众多知名学术研究机构、成熟的细胞治疗研发生态系统以及对生命科学研发的大量投入，保持着区域主导地位。该地区对新技术的早期应用以及对临床级材料品质标准的严格把控，巩固了其作为先进细胞冷冻产品和服务最大市场的地位。

儘管成长要素强劲，但市场仍面临一些技术和营运方面的挑战。传统的冷冻保护剂，例如二甲基亚砜（DMSO），虽然有效，但对于某些敏感细胞类型和临床应用而言，其毒性问题仍令人担忧，因此需要改进配方。此外，冷冻保存是一项技术复杂的过程，成功与​​否取决于精确的通讯协定流程，这需要训练有素的人员和标准化的工作流程。冻融过程中的不一致会导致细胞回收率不稳定，进而影响实验和治疗效果，凸显了加强训练和标准化产品的重要性。

竞争格局包括生命科学试剂供应商、专业冷冻保存培养基公司和低温储存设备製造商。差异化优势体现在产品性能（解冻后细胞存活率）、配方创新（不含动物源成分的即用型培养基）、可扩展性、法规遵从性（提供GMP文件）以及提供包含培养基、通讯协定，甚至在某些情况下还包括设备在内的完整解决方案。

总之，细胞冷冻市场正从一项基础实验室技术发展成为支撑未来医疗保健和药物研发的关键工业化流程。其成长与细胞疗法的进步以及生物样本在研究中日益增长的价值密不可分。未来的发展将受到以下因素的影响：新一代冷冻保护剂的持续创新、自动化和封闭式流程的整合以提高可重复性，以及治疗性细胞冷冻保存全球标准的建立。随着生物经济的扩张，可靠地「暂停」和重新启动活细胞的能力仍将是一项基础性技术，确保该市场在生命科学价值链中保持核心地位并不断提升。

本报告的主要优势：

• 深入分析：获得主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
• 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略进入市场的机会。
• 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
• 可操作的建议：利用这些见解，在动态环境中製定策略决策，发展新的业务流和收入来源。
• 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

本报告的使用范例

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

• 2021年至2025年的历史数据和2026年至2031年的预测数据
• 成长机会、挑战、供应链前景、法规结构与趋势分析
• 竞争定位、策略和市场占有率分析
• 按业务板块和地区（包括国家）分類的收入和预测评估
• 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

• 市场概览
• 市场定义
• 调查范围
• 市场区隔

第三章 商业情境

• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析
• 产业价值链分析
• 政策与法规
• 策略建议

第四章 技术展望

第五章 依培养基类型分類的细胞冻存市场

• 介绍
• 甘油
• 二甲基亚砜（DMSO）

第六章 细胞冷冻市场：依应用领域划分

• 介绍
• 干细胞
• 哺乳动物细胞
• 其他的

第七章 依最终使用者分類的细胞冷冻市场

• 介绍
• 製药和生物技术公司
• 学术和研究机构
• 其他的

第八章 细胞冷冻市场：依地区划分

• 介绍
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他的
• 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
• 中东和非洲
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他的
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 印尼
  • 泰国
  • 其他的

第九章 竞争格局与分析

• 主要企业和策略分析
• 市占率分析
• 合併、收购、协议和合作
• 竞争对手仪錶板

第十章：公司简介

• Merch KgaA
• Sartorius
• Amsbio（Europa Biosite）
• Cell Biologics, Inc.
• Avantor, Inc.
• NIPPON Genetics EUROPE
• Thermo Fisher Scientific Inc.
• BioLife Solutions Inc.
• STEMCELL Technologies Inc.
• Takara Bio Inc.

第十一章附录

• 货币
• 先决条件
• 基准年和预测年时间表
• 相关人员的主要收益
• 调查方法
• 简称

Cell Freezing Market, at a 7.9% CAGR, is expected to grow to USD 477.361 million in 2031 to USD 302.566 million in 2025.

The cell freezing market, encompassing cryopreservation media, equipment, and associated consumables, is a foundational and growing segment within the life sciences and biotechnology industries. Cryopreservation is the process of preserving cells at ultra-low temperatures, typically below -80°C or in liquid nitrogen, to halt all biological activity and ensure long-term viability and functionality. This technology is critical for preserving valuable biological materials, from research cell lines and primary cells to therapeutic cell products. The market's expansion is driven by the advancement of cell-based therapies, the growing infrastructure for biobanking, continuous technological improvements in preservation protocols, and the rising prevalence of chronic diseases that fuel cellular research.

A primary and powerful driver is the accelerating development and commercialization of cell-based therapies. The fields of regenerative medicine, immunotherapy, and stem cell therapy are fundamentally reliant on robust cryopreservation. Therapies such as CAR-T cells, mesenchymal stem cell treatments, and other advanced therapeutic medicinal products (ATMPs) require that living cellular material be stored, transported, and distributed without loss of potency or function. Cell freezing enables the creation of off-the-shelf allogeneic therapies and ensures the reliable supply chain for autologous treatments, making it an indispensable component of the therapeutic development and delivery pipeline.

Concurrently, the market benefits from the expanding scope and scale of biobanking activities worldwide. Biorepositories for academic research, pharmaceutical R&D, clinical trials, and population health studies all depend on high-integrity, long-term cell storage. The preservation of patient-derived cells, genetically engineered lines, and disease models is essential for biomedical discovery. Institutional, government, and commercial investments in biobanking infrastructure directly translate into sustained demand for high-quality cryopreservation media, specialized storage containers, and reliable cryogenic storage systems.

Technological advancements in cryoprotective agents (CPAs) and freezing methodologies are critical enablers of market growth and application expansion. Research focuses on improving post-thaw cell viability, recovery, and functionality by developing less toxic, serum-free, and sometimes DMSO-free cryopreservation media. Innovations also include controlled-rate freezing equipment that optimizes the cooling curve to minimize ice crystal formation and cellular damage. The development of standardized, GMP-grade freezing protocols is particularly important for clinical and therapeutic applications, where consistency and regulatory compliance are paramount.

The rising global burden of chronic and degenerative diseases acts as an indirect yet significant market driver. Research into conditions such as cancer, cardiovascular disease, neurodegenerative disorders, and diabetes increasingly utilizes cellular models, patient-derived samples, and cell-based screening platforms. This research intensity generates substantial volumes of valuable cellular material that must be preserved for longitudinal studies, replication of experiments, and future use, thereby fueling demand for reliable cryopreservation solutions across academic and industrial laboratories.

Governmental and institutional support for life sciences research further stimulates the market. Public funding initiatives for stem cell research, regenerative medicine, and personalized medicine often include provisions for supporting core facilities, which encompass biobanking and cryopreservation capabilities. This funding environment encourages the adoption of advanced freezing technologies and supports the operational costs of long-term cell storage.

Geographically, North America maintains a leading position, driven by a concentration of biotechnology and pharmaceutical companies, leading academic research institutions, a mature ecosystem for cell therapy development, and significant investment in life sciences R&D. The region's early adoption of new technologies and stringent focus on quality standards for clinical-grade materials reinforces its role as the largest market for sophisticated cell freezing products and services.

Despite strong growth drivers, the market faces specific technical and operational challenges. The toxicity of traditional cryoprotectants like DMSO, though effective, remains a concern for some sensitive cell types and clinical applications, driving the need for improved formulations. Furthermore, cryopreservation is a technically demanding process; successful outcomes depend on precise protocol execution, requiring trained personnel and standardized workflows. Inconsistencies in freezing or thawing can lead to variable cell recovery and compromised experimental or therapeutic results, highlighting the need for robust training and standardized products.

The competitive landscape includes life science reagent suppliers, specialized cryopreservation media companies, and manufacturers of cryogenic storage equipment. Differentiation is based on product performance (post-thaw viability), formulation innovation (e.g., animal-component-free, ready-to-use media), scalability, regulatory support (GMP documentation), and the provision of comprehensive solutions that include media, protocols, and sometimes equipment.

In conclusion, the cell freezing market is evolving from a basic laboratory technique to a critical, industrialized process underpinning the future of medicine and discovery. Its growth is inextricably linked to the progress of cell therapy and the expanding value of biological samples in research. Future development will be shaped by the continued innovation of next-generation cryoprotectants, the integration of automation and closed-system processing to enhance reproducibility, and the establishment of global standards for the cryopreservation of therapeutic cells. As the bioeconomy expands, the ability to reliably "pause" and restart living cells will remain a cornerstone capability, ensuring the market's central and growing role in the life sciences value chain.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2021 to 2025 & forecast data from 2026 to 2031
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Cell Freezing Market Segmentation

• By Media Type
• Glycerol
• Dimethyl Sulfoxide (DMSO)
• By Application
• Stem Cells
• Mammalian Cells
• Others
• By End-User
• Pharmaceutical & Biotech Companies
• Academic & Research Institutes
• Others
• By Geography
• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• India
• Japan
• South Korea
• Indonesia
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CELL FREEZING MARKET BY MEDIA TYPE

• 5.1. Introduction
• 5.2. Glycerol
• 5.3. Dimethyl Sulfoxide (DMSO)

6. CELL FREEZING MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Stem Cells
• 6.3. Mammalian Cells
• 6.4. Others

7. CELL FREEZING MARKET BY END-USER

• 7.1. Introduction
• 7.2. Pharmaceutical & Biotech Companies
• 7.3. Academic & Research Institutes
• 7.4. Others

8. CELL FREEZING MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. USA
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Others
• 8.4. Europe
  • 8.4.1. Germany
  • 8.4.2. France
  • 8.4.3. United Kingdom
  • 8.4.4. Spain
  • 8.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. UAE
  • 8.5.3. Others
• 8.6. Asia Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Indonesia
  • 8.6.6. Thailand
  • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Merch KgaA
• 10.2. Sartorius
• 10.3. Amsbio (Europa Biosite)
• 10.4. Cell Biologics, Inc.
• 10.5. Avantor, Inc.
• 10.6. NIPPON Genetics EUROPE
• 10.7. Thermo Fisher Scientific Inc.
• 10.8. BioLife Solutions Inc.
• 10.9. STEMCELL Technologies Inc.
• 10.10. Takara Bio Inc.

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations